Home Medizin Die neuesten Erkenntnisse zu großen Brustkrebsstudien

Die neuesten Erkenntnisse zu großen Brustkrebsstudien

von NFI Redaktion

Industry researchers were present at the San Antonio Breast Cancer Symposium (SABCS) 2023 to report on the latest findings on a range of cancer treatments and update several Phase-3 studies. Medical News from Medscape presented a summary of five studies that could be of particular interest to oncologists.

NATALEE (Ribociclib):
The final results of the NATALEE study on disease-free survival with Ribociclib were presented at SABCS. NATALEE randomized 1748 patients with hormone receptor-positive, HER2-negative early-stage II and III breast cancer to receive adjuvant treatment with an aromatase inhibitor (Letrozole or Anastrozole) for 60 months or longer, and 2549 patients to receive the aromatase inhibitor therapy plus Ribociclib for 3 years. In an interim analysis, the combination of Ribociclib and aromatase inhibitor showed a significant benefit in invasive disease-free survival compared to an aromatase inhibitor alone. The 3-year survival without invasive disease favored the Ribociclib group, with the overall survival also favoring the Ribociclib group.

KATHERINE (T-DM1):
The final results of the Phase-3 KATHERINE study confirmed the benefit of adjuvant Ado-Trastuzumab-Emtansin (T-DM1) over standard Trastuzumab in HER2-positive breast cancer. The 7-year invasive disease-free survival was superior with T-DM1 compared to Trastuzumab, with consistent benefits across all subgroups.

APHINITY (Pertuzumab):
The APHINITY study showed that patients with early-stage HER2-positive breast cancer benefited from adding Pertuzumab to adjuvant Trastuzumab plus chemotherapy, regardless of ER and HER2 expression levels. Patients with HER2-low, ER-positive disease showed the greatest benefit.

KEYNOTE-522 (Pembrolizumab):
Updated results from KEYNOTE-522 continued to demonstrate the benefit of neoadjuvant/adjuvant Pembrolizumab over Placebo in early-stage triple-negative breast cancer. The addition of Pembrolizumab remained beneficial across subgroups.

EMBER (Imlunestrant):
The EMBER study tested Imlunestrant, a selective ER degrader, in combination with Abemaciclib plus or minus an aromatase inhibitor in patients with advanced ER-positive, HER2-negative breast cancer. Phase-1 trials showed promising efficacy, and Phase-3 trials are ongoing.

The studies were funded by the companies producing the various compounds, and the investigators reported associations with them and other companies.

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.